⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12131751 | 0.86 | USP2 (0.55) | — | |
| SCHEMBL1499651 | 0.85 | KMT2A (0.52) | — | |
| SCHEMBL7289085 | 0.83 | KMT2A (0.50) | — | |
| SCHEMBL861034 | 0.81 | KMT2A (0.57) | — | |
| SCHEMBL22917014 | 0.81 | KMT2A (0.57) | — | |
| SCHEMBL23809566 | 0.80 | USP2 (0.44) | — | |
| SCHEMBL17777241 | 0.79 | ALDH1A1 (0.58) | — | |
| SCHEMBL23188735 | 0.79 | ALDH1A1 (0.58) | — | |
| SCHEMBL100593 | 0.79 | — | — | |
| SCHEMBL23839910 | 0.79 | ALDH1A1 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421533-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2018-10-17 | — | — | EP | claimed |
| US-9757368-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2017-09-12 | — | — | US | claimed |
| WO-2013186612-A1 | THE USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BET (BROMODOMAIN AND EXTRA TERMINAL DOMAIN) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-12-19 | — | — | WO | claimed |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | claimed |
| CN-102458405-A | Novel anti-inflammatory agents | RESVERLOGIX CORP | 2012-05-16 | — | — | CN | claimed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | claimed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | claimed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | claimed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | claimed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | claimed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | claimed |
| US-6479488-B1 | GOOD IN VITRO AFFINITY FOR THE STRYCHNINE INSENSITIVE GLYCINE BINDING SITE ASSOCIATED WITH THE NMDA RECEPTOR COMPLEX BUT ALSO GOOD IN VIVO ACTIVITY WHEN ADMINISTERED SYSTEMICALLY | GLAXO WELLCOME SPA (IT) | 2002-11-12 | — | — | US | claimed |
| EP-0922034-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS EAA ANTAGONISTS | GLAXO WELLCOME SPA (IT) | 2002-07-24 | — | — | EP | claimed |
| EP-0922034-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS EAA ANTAGONISTS | GLAXO WELLCOME S.p.A. (IT) | 1999-06-16 | — | — | EP | claimed |
| WO-1998007704-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS EAA ANTAGONISTS | GLAXO WELLCOME S.P.A. (IT) | 1998-02-26 | — | — | WO | claimed |
| CN-107252429-B | Novel anti-inflammatory agent | 雷斯韦洛吉克斯公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-3431086-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2020-06-17 | — | — | EP | disclosed |
| EP-0860435-A1 | Pyridazin-3-one derivatives and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-08-26 | — | — | EP | disclosed |
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |